Additionally, On November 23, 2020, we entered the Subscription Agreements with the PIPE Investors pursuant to which the PIPE Investors agreed to purchase an aggregate of 14,000,000 shares of Apex Common Stock (the “PIPE Shares”), at a purchase price of $10.00 per share for an aggregate purchase price of $140,000,000, in one or more private placement transactions (the “Private Placements”). The closing of the Private Placements pursuant to the Subscription Agreements is contingent upon, among other customary closing conditions, the concurrent consummation of the Proposed Transactions. The purpose of the Private Placements is to raise additional capital for use by the combined company following the Closing. The Subscription Agreements were each subsequently amended to extend the Outside Date (as defined therein) to July 21, 2021.
In May 2021, we entered into Amendment No. 1 to Warrant Agreement with Continental Stock Transfer & Trust Company to correct a defective provision.
On July 1, 2021 (“Closing Date”), the Company and AvePoint consummated the closing of the transactions contemplated by the Business Combination Agreement and Plan of Reorganization, following the approval at a special meeting of the stockholders of the Company held on June 30, 2021.
On the Closing Date, the PIPE investors purchased from the Company an aggregate of 14,000,000 shares of Common Stock, for a purchase price of $10.00 per share and an aggregate purchase price of $140.0 million.
We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception to June 30, 2021 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, following the Initial Public Offering, identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination. We generate
non-operating
income in the form of interest income on marketable securities held in the trust account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing a Business Combination.
For the three months ended June 30, 2021, we had net loss of $18,318,637, which consisted of interest earned on marketable securities held in the Trust Account of $8,482, offset by a change in the fair value of the warrant liability of $13,945,650, operating costs of $4,331,469, and franchise taxes of $50,000.
For the six months ended June 30, 2021, we had net income of $9,992,975, which consisted of a change in the fair value of the warrant liability of $16,226,200 and interest earned on marketable securities held in the Trust Account of $40,323, offset by operating costs of $6,173,548 and franchise taxes of $100,000.
For the three months ended June 30, 2020, we had net loss of $14,365,840, which consisted of interest earned on marketable securities held in the Trust Account of $131,366, offset by a change in the fair value of the warrant liability of $14,210,600, operating costs of $213,837, franchise taxes of $50,000, and provision for income taxes $22,769.
For the six months ended June 30, 2020, we had net loss of $9,256,155, which consisted of interest earned on marketable securities held in the Trust Account of $1,583,780, offset by a change in the fair value of the warrant liability of $9,916,600, operating costs of $408,120, and franchise taxes of $100,000, and provision for income taxes of $415,215.
Liquidity and Capital Resources
On September 19, 2019, we consummated the Initial Public Offering of 35,000,000 Units, which included the partial exercise by the underwriters of the over-allotment option to purchase an additional 4,500,000 Units, at $10.00 per Unit, generating gross proceeds of $350,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 810,000 Placement Units to our Sponsor and Cantor at a price of $10.00 per Unit, generating gross proceeds of $8,100,000.
Following the Initial Public Offering, the exercise of the over-allotment option and the sale of the Placement Units, a total of $350,000,000 was placed in the trust account. We incurred $19,806,442 in transaction costs, including $6,100,000 of underwriting fees, $13,150,000 of deferred underwriting fees and $556,442 of other offering costs.
For the six months ended June 30, 2021, cash used in operating activities was $453,156. Net income of $9,992,975 was impacted by interest earned on marketable securities held in the Trust Account of $40,323, change
(non-cash
gain) in the fair value of the warrant liability of $16,226,200 and changes in operating assets and liabilities, which provided $5,820,393 of cash from operating activities.